Welcome to our dedicated page for OneMedNet news (Ticker: ONMD), a resource for investors and traders seeking the latest updates and insights on OneMedNet stock.
OneMedNet Corporation (NASDAQ: ONMD) is frequently featured in news coverage for its role as a curator and provider of regulatory-grade, AI-ready Real-World Data through its iRWD™ platform. Company announcements highlight developments across its healthcare provider network, subscription offerings, technology partnerships, and relationships with life sciences, medical device, and healthcare AI organizations.
News about OneMedNet often focuses on expansion of its iRWD™ network, including increases in the number of provider sites, de-identified patient records, and clinical exams available for research and analytics. The company also reports on new subscription agreements and master service arrangements that provide customers with ongoing access to curated, multimodal datasets for AI model development, Real-World Evidence programs, and clinical research.
Another key theme in OneMedNet’s news flow is its collaboration with Palantir Technologies. Press releases describe how Palantir’s Artificial Intelligence Platform and Foundry environment are integrated with OneMedNet’s network to enable faster cohort discovery, AI-driven de-identification, and natural-language search across regulatory-grade Real-World Data. Coverage of industry events such as RSNA and ISPOR Europe frequently includes demonstrations of OneMedNet’s redesigned data exploration and cohort-building platform.
Investors and analysts following ONMD can also find updates on strategic partnerships, such as the company’s collaboration with Medcase in healthcare data annotation, and commentary on trends in demand for large-scale Real-World Data subscriptions. For a consolidated view of these developments, the ONMD news page on Stock Titan aggregates press releases, event-related updates, and other public communications so readers can review how OneMedNet’s strategy and operations are being presented over time.
OneMedNet (Nasdaq: ONMD), a leading curator of regulatory-grade Real World Data, has announced a $4.6 million private placement with institutional investors, including affiliates of Off the Chain Capital and Discovery Capital Management. The placement closed on July 25, 2024, with the company selling shares at prices meeting Nasdaq's minimum requirements. OneMedNet plans to use the net proceeds for working capital and general corporate purposes, with $1.8 million already allocated to purchase Bitcoin. The private placement involved the sale of common stock and pre-funded warrants, with the company agreeing to file a registration statement for the resale of the issued shares and those underlying the warrants.
OneMedNet (Nasdaq: ONMD) has announced Cytel Inc. as its newest alliance partner. The partnership involves OneMedNet utilizing its iRWD™ network and platform to provide Cytel with regulatory-grade clinical data. OneMedNet's platform includes over 121 million clinical exams from more than 31 million patients across 1,400+ healthcare sites.
This collaboration will enable Cytel's customers in the biotech and pharma sectors to access ONMD's data through Cytel's Fit For Purpose Data Tool. The partnership aims to foster innovation in trial design, observational studies, and AI/ML model development, focusing on therapeutic areas such as neurologic disorders, oncology, and cardiology.
OneMedNet (Nasdaq: ONMD) has announced several important updates. The company has dismissed its former auditors, BF Borgers, after they were banned by the SEC, and appointed WithumSmith+Brown as the new auditing firm.
OneMedNet has regained compliance with Nasdaq's minimum bid price rule, maintaining a stock price of at least $1.00 for ten consecutive business days.
The company has entered into a standby equity purchase agreement with Yorkville Advisors Global, securing up to $25 million in funding.
However, due to the auditor change, OneMedNet has delayed filing its quarterly Form 10-Q, receiving a non-compliance notice from Nasdaq. The company has 60 days to submit a compliance plan.
OneMedNet continues to trade on The Nasdaq Capital Market under the symbol ONMD.
OneMedNet (NASDAQ: ONMD) has entered into a significant data license agreement with a leading U.S.-based global clinical trial design and software company. This partnership will utilize OneMedNet's proprietary iRWD™ platform to securely manage regulatory-grade clinical data, including electronic health records, lab results, and medical imaging. The agreement aims to expand OneMedNet's commercial reach within the global life sciences industry and accelerate the development of new medical therapies. The collaboration is expected to generate a robust funnel of business opportunities through a referral licensing model.
OneMedNet (Nasdaq: ONMD), a leader in regulatory-grade Real World Data (RWD), has joined the Amazon Web Services (AWS) Partner Network (APN) and secured a new client, a computational biotechnology organization, through the AWS Marketplace.
The APN is a global community leveraging AWS programs and resources to build, market, and sell offerings.
OneMedNet President and CEO Aaron Green highlighted the anticipated rapid growth and the advantages of being part of the APN, emphasizing access to comprehensive clinical data via the iRWD™ network.
The new client praised the ease of accessing OneMedNet's curated clinical data through the AWS Marketplace, enhancing their research and development capabilities.
OneMedNet announced a three-year Master Services Agreement with a top-10 global medical technology company, impacting over 150 million patients annually.
The agreement leverages OneMedNet's iRWD™ platform to securely de-identify, search, and curate regulatory-grade clinical data.
This deal highlights growing industry adoption of OneMedNet's platform and aims to enhance the customer's competitive positioning through better-informed decision-making.
OneMedNet announced a significant expansion of its iRWD™ network and platform, boasting a more than five-fold increase.
The company has partnered with new entities, including a nationwide medical records custodian, increasing its network to 1,402 healthcare system and provider partner sites, 31 million patients, and 121.4 million clinical exams.
This growth represents a 472% increase in partner sites, a 170% rise in patients, and a 122% bump in clinical exams since the end of 2023.
CEO Aaron Green emphasized that this expansion aligns with OneMedNet's strategy to leverage real-world data for healthcare innovation.
OneMedNet , a leading curator of precision curated regulatory-grade Real World Data, will participate in the EF Hutton Annual Global Conference on May 15, 2024. The company's President & CEO and Founder & CMO will be presenting at the event, with management holding one-on-one investor meetings.
OneMedNet (Nasdaq: ONMD) has joined ClinEco Inc., a platform that enhances access and distribution for clinical research. This move validates OneMedNet's Real World Data platform within the clinical trial ecosystem. Aaron Green, President and CEO of OneMedNet, expressed excitement at becoming part of this community. ClinEco serves as a networking hub for clinical trial stakeholders, fostering collaboration and innovation in the life sciences sector.
Summary not available.